EA201800067A1 - Полисахаридные вакцинные препараты и способ промышленного получения бактериальных полисахаридов - Google Patents

Полисахаридные вакцинные препараты и способ промышленного получения бактериальных полисахаридов

Info

Publication number
EA201800067A1
EA201800067A1 EA201800067A EA201800067A EA201800067A1 EA 201800067 A1 EA201800067 A1 EA 201800067A1 EA 201800067 A EA201800067 A EA 201800067A EA 201800067 A EA201800067 A EA 201800067A EA 201800067 A1 EA201800067 A1 EA 201800067A1
Authority
EA
Eurasian Patent Office
Prior art keywords
neisseria meningitidis
meningitididis
vaccine
polysaccharides
neisseria
Prior art date
Application number
EA201800067A
Other languages
English (en)
Other versions
EA039487B1 (ru
Inventor
Кришна Муртхи Элла
Ашавани Кумар
Венкатесан Рамасвами
Волети Сабрахманя Рамачандра Муртхи
Original Assignee
Бхарат Байотек Интернэшнл Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бхарат Байотек Интернэшнл Лимитед filed Critical Бхарат Байотек Интернэшнл Лимитед
Publication of EA201800067A1 publication Critical patent/EA201800067A1/ru
Publication of EA039487B1 publication Critical patent/EA039487B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Представленное изобретение относится к области комбинированных вакцинных композиций, которые являются эффективными против всех форм менингококковых заболеваний, а также брюшного тифа. Вакцинные препараты содержат антигены из капсульных полисахаридов Neisseria meningitidis A, Neisseria meningitidis C, Neisseria meningitidis Y, Neisseria meningitidis W135, Neisseria meningitidis X, Vi капсульного полисахарида Salmonella typhi (ViPs) или капсульных ViPs, конъюгированных с белком-носителем столбнячного анатоксина (ViPs-TT). Данное изобретение также относится к усовершенствованным способам, особенно к использованию улучшенной питательной среды и улучшенного способа последующей обработки и промышленной очистки капсульных полисахаридов. Вакцина не содержит какого-либо животного компонента или спирта и полностью соответствует религиозным чувствам различных этнических групп. Композиция является высокоэффективной и стабильной, еще и экономически эффективной и доступной, особенно для стран с низким и средним уровнем дохода и стран с низким доходом.
EA201800067A 2015-07-04 2016-07-04 Комбинированные полисахаридные вакцинные композиции и способ получения бактериальных капсульных полисахаридов EA039487B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3426CH2015 2015-07-04
PCT/IN2016/050218 WO2017006349A1 (en) 2015-07-04 2016-07-04 Polysaccharide vaccine formulations and processes for industrial production of bacterial polysaccharides

Publications (2)

Publication Number Publication Date
EA201800067A1 true EA201800067A1 (ru) 2018-11-30
EA039487B1 EA039487B1 (ru) 2022-02-01

Family

ID=57686117

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201800067A EA039487B1 (ru) 2015-07-04 2016-07-04 Комбинированные полисахаридные вакцинные композиции и способ получения бактериальных капсульных полисахаридов

Country Status (7)

Country Link
US (1) US10543266B2 (ru)
EP (1) EP3316903A4 (ru)
AU (2) AU2016290233A1 (ru)
EA (1) EA039487B1 (ru)
MY (1) MY183392A (ru)
WO (1) WO2017006349A1 (ru)
ZA (1) ZA201800398B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019002489A (es) 2016-09-02 2019-10-21 Sanofi Pasteur Inc Vacuna contra neisseria meningitidis.
BR112019022868A2 (pt) 2017-05-05 2020-05-19 Serum Institute Of India Private Limited método para remoção de impurezas de preparações à base de polissacarídeo capsular bacteriano
RU2019140344A (ru) * 2017-05-17 2021-06-17 Мсд Веллком Траст Хиллеман Лабораторис Пвт. Лтд. Получение бактериальных полисахаридов
KR20200021933A (ko) * 2017-06-27 2020-03-02 엠에스디 웰컴 트러스트 힐레맨 랩스 피브이티. 리미티드 나이세리아 메닌지티디스 혈청군 x 캡슐 다당류의 급속 고수율 정제 방법
WO2019175900A1 (en) * 2018-03-16 2019-09-19 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Purification of neisseria meningitidis polysaccharides
JOP20200214A1 (ar) * 2019-09-03 2021-03-03 Serum Institute Of India Pvt Ltd تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها
US20210070890A1 (en) 2019-09-06 2021-03-11 Serum Institute Of India Private Limited Method for obtaining purified bacterial polysaccharides
CN115478033A (zh) * 2022-10-13 2022-12-16 艾美卫信生物药业（浙江）有限公司 一种脑膜炎球菌发酵培养方法、发酵液、荚膜多糖、应用
CN115478034B (zh) * 2022-10-13 2023-04-18 艾美卫信生物药业（浙江）有限公司 一种脑膜炎球菌发酵培养方法、发酵液、精制多糖、应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491517B2 (en) 2006-07-19 2009-02-17 Jeeri R Reddy Method of producing meningococcal meningitis vaccine for Neisseria meningitidis serotypes A,C,Y, and W-135
MX354103B (es) 2012-01-30 2018-02-13 Serum Inst India Ltd Composicion inmunogenica.
WO2014009971A2 (en) * 2012-07-07 2014-01-16 Bharat Biotech International Limited Non-alcoholic vaccine compositions free from animal- origin and process for preparation thereof
CA2892035C (en) 2012-11-21 2019-11-05 Serum Institute Of India Ltd. Production of neisseria meningitidis x capsular polysaccharide

Also Published As

Publication number Publication date
EP3316903A1 (en) 2018-05-09
EP3316903A4 (en) 2019-01-09
MY183392A (en) 2021-02-18
US20180185465A1 (en) 2018-07-05
EA039487B1 (ru) 2022-02-01
US10543266B2 (en) 2020-01-28
WO2017006349A1 (en) 2017-01-12
ZA201800398B (en) 2019-07-31
AU2016290233A1 (en) 2018-01-25
AU2022203878A1 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
EA201800067A1 (ru) Полисахаридные вакцинные препараты и способ промышленного получения бактериальных полисахаридов
EP3616716A3 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EA035991B9 (ru) Новый полисахарид и его применения
BR112018071198A2 (pt) métodos para melhorar a produção agrícola de aves pela administração de consórcios microbianos ou de cepas purificadas dos mesmos
GB2551642A (en) Methods and compositions relating to microbial treatment and diagnosis of dis-orders
EA201990091A1 (ru) Способ получения и очистки натриевой соли гиалуроновой кислоты
EA201700336A1 (ru) Композиция, включающая хитин и переваримые белки
WO2016179034A3 (en) Methods and compositions for stimulating immune response using potent immunostimulatory rna motifs
EA201992175A1 (ru) Композиции и способы, включающие пробиотические молекулы
MX2013012219A (es) Método de administración de vacunas.
WO2016025933A3 (en) Substituted polycyclic antibacterial compounds
ME00982B (me) Oslabljeni sojevi bakterije mycoplasma gallisepticum
EA202091690A1 (ru) Иммуногенная композиция, содержащая стафилококковые антигены
EA201990998A1 (ru) Фармацевтические составы и способы их получения
EP4241786A3 (en) Methods and compositions for stimulating immune response
EA201792512A1 (ru) Составы для доставки антигенов респираторного синтициального вируса и норовируса в тонкий кишечник
PH12018501205A1 (en) Synthetic vaccines against streptococcus pneumoniae serotype 2
EA202190546A1 (ru) Способы лечения инфекций с применением бактерий
BR112018074910A2 (pt) composição imunológica, e, método de indução de uma resposta imunológica contra o vírus da influenza equina em um sujeito
EA201892003A1 (ru) Лечение атопического дерматита собак
MX2020001820A (es) Metodos para reforzar las respuestas inmunitarias.
MX2019006915A (es) Metodo para el control de enfermedades bacterianas de plantas utilizando derivados de carboxamida.
MA39228A1 (fr) Compositions à utiliser pour le traitement d'états allergiques
EA201691699A1 (ru) Производство йогурта
MX2021015155A (es) Polisacaridos de ramnosa.